Vantage logo

Forty Seven bucks the trend

Tackling the CD47 pathway has seen off several industry players, but Forty Seven continues proudly flying the flag.

Vantage logo

Lilly jumps the gun with Dermira deal

The $1.1bn that Lilly is paying for lebrikizumab looks low ball, but competing against Dupixent will not come cheap. And then there are the Roche payments.